Selecta Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Selecta Biosciences (NASDAQ: SELB), a clinical-stage biotechnology firm, announced its CEO, Carsten Brunn, Ph.D., will participate in two upcoming investor conferences. The first is the Jefferies Virtual Gene Therapy/Editing Summit on October 1, 2020, at 4:30 p.m. ET. The second is the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 2:30 p.m. ET. Both events will be accessible via live webcasts on the company’s website. Selecta aims to develop immune tolerance therapies using its ImmTOR™ platform, with clinical trials expected to begin in early 2021.

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR^TM, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in October:

Jefferies Virtual Gene Therapy/Editing Summit
Date: Thursday, October 1, 2020
Fireside chat time: 4:30 p.m. ET

Chardan Virtual 4^th Annual Genetic Medicines Conference
Date: Monday, October 5, 2020
Fireside chat time: 2:30 p.m. ET

Live webcasts will be available in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.

For Investors:
Lee M. Stern
Solebury Trout
+1-646-378-2922
lstern@soleburytrout.com

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

FAQ

What are the upcoming conferences for Selecta Biosciences in October 2020?

Selecta Biosciences will participate in the Jefferies Virtual Gene Therapy/Editing Summit on October 1, 2020, and the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020.

Who is speaking at the Selecta Biosciences conferences?

Carsten Brunn, Ph.D., the CEO of Selecta Biosciences, will be speaking at both conferences.

How can I watch the Selecta Biosciences investor conferences?

Live webcasts of the conferences will be available in the Investors & Media section of the Selecta Biosciences website.

What is the focus of Selecta Biosciences' ImmTOR™ platform?

Selecta Biosciences' ImmTOR™ platform focuses on developing tolerogenic therapies to mitigate unwanted immune responses.

When is Selecta Biosciences expected to start clinical trials for their programs?

Selecta Biosciences anticipates starting clinical trials for its first program in early 2021.